Clinical Interest in Exome-Based Analysis of Somatic Mutational Signatures for Non-Small Cell Lung Cancer.
Fiche publication
Date publication
septembre 2024
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Mme TRUNTZER Caroline, Dr DERANGERE Valentin
Tous les auteurs :
Peroz M, Mananet H, Roussot N, Kaderbhai CG, Derangère V, Truntzer C, Ghiringhelli F
Lien Pubmed
Résumé
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality. This study investigates the clinical interest of whole exome sequencing (WES) for analyzing somatic mutational signatures in patients with advanced or metastatic NSCLC treated with the current standard of care.
Mots clés
immune checkpoint inhibitors, non-small cell lung cancer, prognostic biomarkers, somatic mutational signatures, whole exome sequencing
Référence
Cancers (Basel). 2024 09 9;16(17):